home / stock / rvnc / rvnc news

RVNC News and Press, Revance Therapeutics Inc. From 01/08/24

Stock Information
Company Name: Revance Therapeutics Inc.
Stock Symbol: RVNC
Market: NASDAQ
Website: revance.com
Menu
RVNC RVNC Quote RVNC Short RVNC News RVNC Articles RVNC Message Board
Get RVNC Alerts

News, Short Squeeze, Breakout and More Instantly...
RVNC - SNMP, VERO and PRAX among mid-day movers

2024-01-08 12:31:25 ET Gainers: Harpoon Therapeutics ( HARP ) +112% . Ambrx Biopharma ( AMAM ) +101% . Nkarta ( NKTX ) +47% . Mountain Crest Acquisition Corp IV ( MCAF ) +45% . Spectaire Holdings ( SPEC ) +43% . Neximmune ( ...
RVNC - Revance Therapeutics expects to achieve positive adj EBITDA in 2025

2024-01-08 11:47:12 ET More on Revance Therapeutics Revance Therapeutics: Not Even Daxxify Can Treat Investor Frown Lines Revance Therapeutics, Inc. (RVNC) Q3 2023 Earnings Call Transcript Public Citizen petitions FDA for stricter warnings against Botox, similar drug...

RVNC - Revance Provides Corporate Update, Preliminary Fourth Quarter and Full Year 2023 Financial Results, and Financial Outlook

– Q4 DAXXIFY® volume sold up 22% over Q3, reflecting positive feedback on the product’s performance profile and the new pricing strategy. – Preliminary unaudited Q4 and full year 2023 product revenue (DAXXIFY and RHA® Collection) of between $58 million and $59 m...

RVNC - How the (RVNC) price action is used to our Advantage

2023-12-25 02:40:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
RVNC - Public Citizen petitions FDA for stricter warnings against Botox, similar drugs

2023-12-12 10:33:17 ET More on AbbVie, Evolus, etc. AbbVie: 4 Hidden Keys Investors Must Know To Judge ImmunoGen Acquisition AbbVie: Risky Purchase Of ImmunoGen Could Pay Off Big Time AbbVie: $10 Billion Cancer Deal To Boost Growth AbbVie upgraded at Goldman ...

RVNC - Revance Therapeutics: Not Even Daxxify Can Treat Investor Frown Lines

2023-11-29 12:06:50 ET Summary Revance Therapeutics' share price has been characterised by volatility ever since its IPO - but today shares trade close to an all-time low. The company's focus is on maximising the potential of Daxxify - approved to treat frown lines, and recently a...

RVNC - Revance Therapeutics files for mixed shelf

2023-11-14 17:52:57 ET More on Revance Therapeutics Revance Therapeutics, Inc. (RVNC) Q3 2023 Earnings Call Transcript Revance Therapeutics: Impressive Sales Growth/Concerning Cash Burn Revance's FDA Nod: Beauty, Brains, And Balance Sheets Needham says Abbvie...
RVNC - Revance Therapeutics, Inc. (RVNC) Q3 2023 Earnings Call Transcript

2023-11-08 22:50:20 ET Revance Therapeutics, Inc. (RVNC) Q3 2023 Earnings Conference Call November 08, 2023, 04:30 PM ET Company Participants Jessica Serra - Head, IR, Communications & ESG Mark Foley - CEO Dustin Sjuts - President Toby Schilke - CFO ...

RVNC - Revance Therapeutics GAAP EPS of -$1.63 misses by $0.69, revenue of $56.8M misses by $1.94M

2023-11-08 16:23:27 ET Revance Therapeutics press release ( NASDAQ: RVNC ): Q3 GAAP EPS of -$1.63 misses by $0.69 . Revenue of $56.8M (+95.9% Y/Y) misses by $1.94M . Expects its 2023 GAAP operating expenses to be $545 million to $585 million. Cash, cash equ...

RVNC - Revance Reports Third Quarter 2023 Financial Results, Provides Corporate Update

– Q3 total product revenue of $54.1 million, a YoY increase of 107.5%. – Q3 DAXXIFY® revenue of $22.0 million, and first full year revenue post approval of $71.0 million. – Q3 RHA® Collection revenue of $32.1 million, a YoY increase of 23.2%. – In Augus...
Previous 10 Next 10